{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T07:29:56Z","timestamp":1793777396578,"version":"4.6.1"},"reference-count":37,"publisher":"BMJ","issue":"e2","content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Support Palliat Care"],"accepted":{"date-parts":[[2024,8,5]]},"published-print":{"date-parts":[[2024,11]]},"abstract":"<jats:sec><jats:title>Objective<\/jats:title><jats:p>Osimertinib plays a crucial role in patients with non-small cell lung cancer (NSCLC). However, the haematological toxicities caused by osimertinib in such a population have not been well characterised. This analysis was performed to determine the incidence of osimertinib-related haematological toxicity in patients with NSCLC.<\/jats:p><\/jats:sec><jats:sec><jats:title>Method<\/jats:title><jats:p>A literature search was conducted in PubMed, Embase, Cochrane Library and Web of Science. Eligible studies were included to describe the pooled incidences of anaemia, neutropenia and thrombocytopenia secondary to osimertinib in NSCLC patients.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>1288 patients from 10 studies were enrolled in this study. The overall incidences of osimertinib-related all-grade anaemia, neutropenia and thrombocytopenia in NSCLC patients were 21.1% (95% CI 10.9% to 33.3%), 14.6% (95% CI 5.9% to 26.1%) and 28.4% (95% CI 12.4% to 47.6%), respectively. In items of high-grade haematological toxicities, there were 0.5% (95% CI 0.1% to 1.1%) for anaemia, 2.0% (95% CI 0.3% to 4.6%) for neutropenia and 0.4% (95% CI 0% to 1.1%) for thrombocytopenia.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>There is non-negligible haematological toxicity associated with osimertinib, and it should be taken seriously.<\/jats:p><\/jats:sec>","DOI":"10.1136\/spcare-2024-005113","type":"journal-article","created":{"date-parts":[[2024,8,19]],"date-time":"2024-08-19T17:20:14Z","timestamp":1724088014000},"page":"e1671-e1677","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":2,"title":["Osimerinib haematological toxicities in non-small cell lung cancer: a randomised controlled trials meta-analysis"],"prefix":"10.1136","volume":"14","author":[{"given":"Fangfang","family":"Xiong","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yunzhu","family":"Shen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ting","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yin","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8090-1874","authenticated-orcid":false,"given":"Xuehui","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2024,8,19]]},"reference":[{"key":"2025032703260703000_14.e2.e1671.1","doi-asserted-by":"publisher","DOI":"10.1158\/1055-9965.EPI-19-0221"},{"key":"2025032703260703000_14.e2.e1671.2","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21492"},{"key":"2025032703260703000_14.e2.e1671.3","doi-asserted-by":"publisher","DOI":"10.1016\/j.mcna.2018.12.006"},{"key":"2025032703260703000_14.e2.e1671.4","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(21)00312-3"},{"key":"2025032703260703000_14.e2.e1671.5","doi-asserted-by":"publisher","DOI":"10.1146\/annurev-pathol-011110-130206"},{"key":"2025032703260703000_14.e2.e1671.6","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa040938"},{"key":"2025032703260703000_14.e2.e1671.7","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-14-3154"},{"key":"2025032703260703000_14.e2.e1671.8","doi-asserted-by":"crossref","first-page":"71","DOI":"10.2165\/00151829-200504020-00001","article-title":"Improving survival and reducing toxicity with chemotherapy in advanced non-small cell lung cancer\u202f: a realistic goal?","volume":"4","author":"Blackhall","year":"2005","journal-title":"Treat Respir Med"},{"key":"2025032703260703000_14.e2.e1671.9","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2001.19.6.1734"},{"key":"2025032703260703000_14.e2.e1671.10","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.32097"},{"key":"2025032703260703000_14.e2.e1671.11","doi-asserted-by":"crossref","first-page":"946","DOI":"10.1016\/j.jtho.2016.05.008","article-title":"The International Association for the Study of Lung Cancer Consensus Statement on Optimizing Management of EGFR Mutation\u2013Positive Non\u2013Small Cell Lung Cancer: Status in 2016","volume":"11","author":"Tan","year":"2016","journal-title":"J Thorac Oncol"},{"key":"2025032703260703000_14.e2.e1671.12","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2017.74.6065"},{"key":"2025032703260703000_14.e2.e1671.13","doi-asserted-by":"publisher","DOI":"10.1021\/jm500973a"},{"key":"2025032703260703000_14.e2.e1671.14","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-14-0337"},{"key":"2025032703260703000_14.e2.e1671.15","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1913662"},{"key":"2025032703260703000_14.e2.e1671.16","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1016\/j.jaccao.2019.10.006","article-title":"Osimertinib-Induced Cardiotoxicity: A Retrospective Review of the FDA Adverse Events Reporting System (FAERS)","volume":"1","author":"Anand","year":"2019","journal-title":"JACC CardioOncol"},{"key":"2025032703260703000_14.e2.e1671.17","article-title":"Rapid drop in blood platelet count and increase in creatinine in non-small cell lung cancer (NSCLC) patients treated with osimertinib","volume":"36","author":"Eide","year":"2018","journal-title":"J C O"},{"key":"2025032703260703000_14.e2.e1671.18","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1713137"},{"key":"2025032703260703000_14.e2.e1671.19","doi-asserted-by":"crossref","first-page":"1098","DOI":"10.1016\/j.jtho.2022.05.006","article-title":"Randomized Phase 2 Study of Osimertinib Plus Bevacizumab Versus Osimertinib for Untreated Patients With Nonsquamous NSCLC Harboring EGFR Mutations: WJOG9717L Study","volume":"17","author":"Kenmotsu","year":"2022","journal-title":"J Thorac Oncol"},{"key":"2025032703260703000_14.e2.e1671.20","doi-asserted-by":"crossref","DOI":"10.1136\/bmj.b2535","article-title":"Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement","volume":"339","author":"Moher","year":"2009","journal-title":"BMJ"},{"key":"2025032703260703000_14.e2.e1671.21","unstructured":"HJTJCJCMLTPMW V . Cochrane handbook for systematic reviews of interventions version 6.4 . Cochrane, 2023."},{"key":"2025032703260703000_14.e2.e1671.22","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1001\/jamaoncol.2020.6758","article-title":"Efficacy of Osimertinib Plus Bevacizumab vs Osimertinib in Patients With EGFR T790M-Mutated Non-Small Cell Lung Cancer Previously Treated With Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitor: West Japan Oncology Group 8715L Phase 2 Randomized Clinical Trial","volume":"7","author":"Akamatsu","year":"2021","journal-title":"JAMA Oncol"},{"key":"2025032703260703000_14.e2.e1671.23","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1016\/j.lungcan.2018.04.012","article-title":"Osimertinib compared docetaxel-bevacizumab as third-line treatment in EGFR T790M mutated non-small-cell lung cancer","volume":"121","author":"Nie","year":"2018","journal-title":"Lung Cancer (Auckl)"},{"key":"2025032703260703000_14.e2.e1671.24","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1612674"},{"key":"2025032703260703000_14.e2.e1671.25","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1016\/j.jtho.2019.02.001","article-title":"Osimertinib Plus Durvalumab versus Osimertinib Monotherapy in EGFR T790M\u2013Positive NSCLC following Previous EGFR TKI Therapy: CAURAL Brief Report","volume":"14","author":"Yang","year":"2019","journal-title":"J Thorac Oncol"},{"key":"2025032703260703000_14.e2.e1671.26","doi-asserted-by":"publisher","DOI":"10.1007\/s11523-021-00794-6"},{"key":"2025032703260703000_14.e2.e1671.27","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.ejca.2021.02.019","article-title":"Osimertinib versus osimertinib plus chemotherapy for non-small cell lung cancer with EGFR (T790M)-associated resistance to initial EGFR inhibitor treatment: an open-label, randomised phase 2 clinical trial","volume":"149","author":"Tanaka","year":"2021","journal-title":"Eur J Cancer"},{"key":"2025032703260703000_14.e2.e1671.28","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2018.09.004"},{"key":"2025032703260703000_14.e2.e1671.29","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa2306434"},{"key":"2025032703260703000_14.e2.e1671.30","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1002\/jcph.1042","article-title":"Pharmacokinetics of Osimertinib in Chinese Patients With Advanced NSCLC: A Phase 1 Study","volume":"58","author":"Zhao","year":"2018","journal-title":"J Clin Pharmacol"},{"key":"2025032703260703000_14.e2.e1671.31","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.20176"},{"key":"2025032703260703000_14.e2.e1671.32","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199705083361906"},{"key":"2025032703260703000_14.e2.e1671.33","doi-asserted-by":"crossref","first-page":"407","DOI":"10.2147\/OTT.S315385","article-title":"Pancytopenia During Osimertinib Treatment in a Patient with EGFR-Mutated Non-Small Cell Lung Cancer","volume":"15","author":"Di Marino","year":"2022","journal-title":"Onco Targets Ther"},{"key":"2025032703260703000_14.e2.e1671.34","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-6143.2012.04019.x"},{"key":"2025032703260703000_14.e2.e1671.35","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0221575","article-title":"Effectiveness and safety of osimertinib in patients with metastatic EGFR T790M-positive NSCLC: an observational real-world study","volume":"14","author":"Cao","year":"2019","journal-title":"PLoS One"},{"key":"2025032703260703000_14.e2.e1671.36","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1093\/jjco\/hyaa067","article-title":"Real-world use of osimertinib for epidermal growth factor receptor T790M-positive non-small cell lung cancer in Japan","volume":"50","author":"Ohe","year":"2020","journal-title":"Jpn J Clin Oncol"},{"key":"2025032703260703000_14.e2.e1671.37","doi-asserted-by":"crossref","first-page":"1152","DOI":"10.1186\/s12885-020-07650-2","article-title":"Effects of reduced platelet count on the prognosis for patients with non-small cell lung cancer treated with EGFR-TKI: a retrospective study","volume":"20","author":"Xu","year":"2020","journal-title":"BMC Cancer"}],"container-title":["BMJ Supportive &amp; Palliative Care"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/spcare-2024-005113","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,27]],"date-time":"2025-03-27T11:02:47Z","timestamp":1743073367000},"score":1,"resource":{"primary":{"URL":"https:\/\/spcare.bmj.com\/lookup\/doi\/10.1136\/spcare-2024-005113"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8,19]]},"references-count":37,"journal-issue":{"issue":"e2","published-online":{"date-parts":[[2024,11,15]]},"published-print":{"date-parts":[[2024,11]]}},"alternative-id":["10.1136\/spcare-2024-005113"],"URL":"https:\/\/doi.org\/10.1136\/spcare-2024-005113","relation":{},"ISSN":["2045-435X","2045-4368"],"issn-type":[{"value":"2045-435X","type":"print"},{"value":"2045-4368","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,8,19]]}}}